Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 3Colorectal Neoplasms 3Pancreatic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Breast Neoplasms 1

Interventions

vandetanib 14cabozantinib 9selpercatinib 6Sorafenib 5Everolimus 5pralsetinib 3Magnetic Resonance Spectroscopy 3Capecitabine 3sargramostim 2lutetium Lu 177 dotatate 2lenvatinib 2Trastuzumab 2Thyroidectomy 2Temozolomide 2Sunitinib 2Specimen Handling 2Octreotide 2High-Energy Shock Waves 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1rovalpituzumab tesirine 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Medullary × yeast-CEA vaccine × Clear all
NCT01856920 2024-07-09

QUILT-3.006 for Recurrent Medullary Thyroid Cancer

NantCell, Inc.

Phase 2 Completed
35 enrolled 9 charts

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡